Alpha-9 Theranostics series B financing

Alpha-9 Theranostics Inc. completed its series B financing for an aggregate US$75 million, to be commited across multiple tranches, led by Nextech Invest, with participation from Frazier Life Sciences, Samsara BioCapital and Quark Venture in addition to existing investors Longitude Capital and BVF Partners.

Alpha-9 is engineering highly effective, bespoke radiopharmaceuticals for the treatment of solid and hematologic malignancies. These molecules are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. The Series B funding will support advancement of the company's five programs into the clinic over the next two years while expanding its early-stage programs.


Joseph A. Garcia Emma Costante


Blake, Cassels & Graydon LLP Goodwin Procter LLP